Because liquid immersion creates two risks a therapeutic facility cannot carry: a cross contamination route between containers through the shared nitrogen itself, and liquid working its way into imperfectly sealed bags and vials, where it expands violently on warming. Vapour phase storage removes both while keeping product comfortably below the glass transition, which is why it has become the default expectation in cell and gene therapy manufacture. The trade is that temperature now depends on level, with a gradient between the liquid surface and the neck that steepens as the level falls, so the vessel must be mapped at commissioning and alarmed against its warmest storage position; the physics is set out in what minus 196 actually means. In practice that makes fill discipline part of the quality system, anchored by in house dispensing from a CryoFill vessel and run in vapour phase steel tanks such as the CryoBank series. The full storage architecture is covered in our guide to cryogenic storage for cell and gene therapy.